Hypofractionation for prostate cancer: a word of caution

Affiliations

¹ Department of Radiation Oncology, Gustave Roussy Cancer Center, Villejuif, France. Electronic address: alberto.bossi@gustaveroussy.fr.
² Department of Radiation Oncology, Gustave Roussy Cancer Center, Villejuif, France.

Comment

Alberto Bossi et al. Lancet Oncol. 2016 Apr.

. 2016 Apr;17(4):406-407.

doi: 10.1016/S1470-2045(15)00626-9. Epub 2016 Mar 9.

¹ Department of Radiation Oncology, Gustave Roussy Cancer Center, Villejuif, France. Electronic address: alberto.bossi@gustaveroussy.fr.
² Department of Radiation Oncology, Gustave Roussy Cancer Center, Villejuif, France.

No abstract available

Comment on

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, Alemayehu WG, Heemsbergen W, Heijmen B, Incrocci L. Aluwini S, et al. Lancet Oncol. 2016 Apr;17(4):464-474. doi: 10.1016/S1470-2045(15)00567-7. Epub 2016 Mar 9. Lancet Oncol. 2016. PMID: 26968359 Clinical Trial.